Fred Alger Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Fred Alger Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$628K	Buy	+32,254	New	+$585K	﹤0.01%	385
2025 Q3	–	Sell	-295,623	Closed	-$14M	–	480
2025 Q2	$14M	Sell	295,623 -347,258	-54%	-$14.1M	0.06%	145
2025 Q1	$25.1M	Sell	642,881 -30,892	-5%	-$1.33M	0.14%	100
2024 Q4	$36.5M	Buy	673,773 +7,199	+1%	+$368K	0.17%	88
2024 Q3	$33.6M	Buy	666,574 +7,545	+1%	+$354K	0.16%	97
2024 Q2	$29M	Sell	659,029 -7,693	-1%	-$326K	0.14%	101
2024 Q1	$33.5M	Sell	666,722 -143,864	-18%	-$7.8M	0.17%	112
2023 Q4	$49M	Sell	810,586 -22,365	-3%	-$1.15M	0.26%	81
2023 Q3	$47.5M	Buy	832,951 +85,346	+11%	+$4.71M	0.27%	91
2023 Q2	$38.1M	Buy	747,605 +640,685	+599%	+$17.2M	0.19%	119
2023 Q1	$2.29M	Buy	+106,920	New	+$1.8M	0.01%	329

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fred Alger Management's MLTX Position: Q2 2026 in Review

Fred Alger Management opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 32,254 shares worth $628K. The stake represents ﹤0.01% of the portfolio and ranks #385 among its holdings. This is a return to the name: Fred Alger Management previously reported a position in MLTX as recently as Q2 2025.

Fred Alger Management first reported a position in MLTX in Q1 2023 and has held it in 11 quarters since. The position peaked at $49M in Q4 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Fred Alger Management held 32,254 shares of MoonLake Immunotherapeutics worth $628K as of Q2 2026.
MoonLake Immunotherapeutics was a new Fred Alger Management position in Q2 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Fred Alger Management's portfolio in Q2 2026, its #385 holding.
Fred Alger Management first reported a position in MoonLake Immunotherapeutics in Q1 2023 and has held it in 11 quarters since.
Fred Alger Management's MoonLake Immunotherapeutics position peaked at $49M in Q4 2023.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.